Ribosomes erythromycin binding

Figure 12 Macrolide modifying enzymes. Macrolide antibiotics such as erythromycin (shown) bind to the large ribosomal subunit through interactions with the 23 S rRNA (A). Chemical modification of the essential desosamine sugar blocks ribosome binding (B).

The erythromycin ribosomal methylase (erm) genes encode 23S ribosomal RNA methylases. This modification results in reduced binding of aU known macrolides, lincosamides, and streptogramin B to the ribosome (MLS resistance). Novel triazine-containing methyltransferase inhibitors that may reverse erm-mediated resistance are under development (46). 

Erythromycin selectively binds to a single site on the 508 ribosomal subunit of 70S bacterial ribosome in the presence of Mg and ions but does not bind to mammalian 80S ribosome [4, 31]. 

Taubman, S. B., Jones, N. R, Young, F. E., and Corcoran, J. W. (1966). Sensitivity and resistance to erythromycin in Bacillus subtilis 168 The ribosomal binding of erythromycin and chloramphenicol. Biochem. Biophys. Acta 123,438-440. 

MECHANISM OF ACTION CUndamycin binds to the 50S subunit of bacterial ribosomes and suppresses protein synthesis. Although clindamycin, erythromycin, and chloramphenicol are not structurally related, they act at sites in close proximity (Figures 46-2 and 46-3), and ribosome binding by one of these drugs may inhibit the interaction of the others. MacroUde resistance due to ribosomal methylation also may produce resistance to clindamycin. Because clindamycin does not induce the methylase, there is cross-resistance only if the enzyme is produced constitutively. Clindamycin is not a substrate for macrolide efflux pumps thus, strains that are resistant to macroUdes by this mechanism are susceptible to clindamycin. 

The macrolide antibiotics (e.g., erythromycin, clarithromycin) bind to the BOS ribosomal subunit of bacteria and inhibit translocation. Clarithromycin was used to treat Neu Moania because he had taken it previously without difficulty. It has less serious side effects than many other antibiotics and is used as an alternative drug in patients, such as Mr. Moania, who are allergic to penicillin. After 1 week of therapy, Mr. Moania recovered from his infection. 

The masking of ertn (erythromycin resistance) ribosome binding site by retarded translation of the erm leader transcript... 

Although the majority of mechanistic studies have used erythromycin, all other macrolides as well as the lincosamides and streptogramins (collectively known as MLS antibiotics) are believed to operate by a similar mechanism [216]. However, each of the groups possesses slightly different, but overlapping, ribosomal binding domains [217]. 

We found that erythromycin binds exclusively to the 52 S subunit of the plastid ribosome. Binding of [ C]erythromycin was followed using an assay which had been used with bacterial ribosomes. At an equilibrium constant of about 8 x 10 mol" for erythromycin binding to 52 S subunits the affinity of Chlamydomonas ribosomes for the antibiotic is one to two orders of magnitude lower than that of bacterial ribosomes. ... 

Ribosomal Protein Synthesis Inhibitors. Figure 5 Nucleotides at the binding sites of chloramphenicol, erythromycin and clindamycin at the peptidyl transferase center. The nucleotides that are within 4.4 A of the antibiotics chloramphenicol, erythromycin and clindamycin in 50S-antibiotic complexes are indicated with the letters C, E, and L, respectively, on the secondary structure of the peptidyl transferase loop region of 23S rRNA (the sequence shown is that of E. coll). The sites of drug resistance in one or more peptidyl transferase antibiotics due to base changes (solid circles) and lack of modification (solid square) are indicated. Nucleotides that display altered chemical reactivity in the presence of one or more peptidyl transferase antibiotics are boxed. 

These agents bind selectively to a region of the SOS ribosomal subunit close to that of chloramphenicol and erythromycin. They block elongation of the peptide chain by inhibition of peptidyl transferase. 

The macrolide erythromycin inhibits protein synthesis and resistance is induced by N -dimethyl-ation of adenine within the 23S rRNA, which results in reduced affinity of ribosomes for antibiotics related to erythromcin (Skinner et al. 1983). Sulfonamides function by binding tightly to chromosomal dihydropteroate synthetase and resistance to sulfonamides is developed in the resistance plasmid through a form of the enzyme that is resistant to the effect of sulfonamides. 

Newer and more generally usefnl macrolide antibiotics include azithromycin (Zithromax) and clarithromycin (Biaxin). These too are wide-spectrum antibiotics and both are semisynthetic derivatives of erythromycin. Like the tetracyclines, the macrolide antibiotics act as protein synthesis inhibitors and also do so by binding specifically to the bacterial ribosome, thongh at a site distinct from that of the tetracyclines. 

Erythromycin inhibits bacterial protein synthesis by reversibly binding with their 50 S ribosomal subunit, thus blocking the formation of new peptide bonds. Erythromycin is classified as a bacteriostatic antibiotic. 

Clindamycin is a chlorine-substituted derivative of lincomycin. However it is more potent and is better absorbed from the gastrointestinal tract and has therefore replaced lincomycin in most situations. Clindamycin is in principle a bacteriostatic agent. Its indications are mainly limited to mixed anaerobic infections. As mentioned above it has a similar mechanism of action as erythromycin. It selectively inhibits bacterial protein synthesis by binding to the same 50s ribosomal subunits. Erythromycin and clindamycin can interfere with each other by competing for this receptor. Also cross-resistance with erythromycin frequently occurs. Resistance is rather chromosomal rather than plasmid mediated and is especially found in cocci and Clostridium difficile. 

Macrolides bind to the SOS ribosomal subunit of bacteria but not to the SOS mammalian ribosome this accounts for its selective toxicity. Binding to the ribosome occurs at a site near peptidyltransferase, with a resultant inhibition of translocation, peptide bond formation, and release of oligopeptidyl tRNA. However, unlike chloramphenicol, the macrolides do not inhibit protein synthesis by intact mitochondria, and this suggests that the mitochondrial membrane is not permeable to erythromycin. 

The lincosamide family of antibiotics includes lin-comycin (Lincocin) and clindamycin (Cleocin), both of which inhibit protein synthesis. They bind to the SOS ri-bosomal subunit at a binding site close to or overlapping the binding sites for chloramphenicol and erythromycin. They block peptide bond formation by interference at either the A or P site on the ribosome. Lincomycin is no longer available for human use in the United States. 

---